Literature DB >> 36065434

Mucormycosis in the Urinary Bladder-the Devil Is in the Details.

Manjeet Kumar1, Pawan Kaundal1, Sunish Sharma2, Kirti Rana1.   

Abstract

Mucormycosis is a fungal infection involving rhinocerebral, pulmonary, cutaneous, gastrointestinal and disseminated forms with high morbidity and mortality with rare involvement of the urinary bladder. Diagnosis is made by examining under a microscope, identifying broad, nonseptate, irregular and ribbon-shaped hyphae. Timely diagnosis and starting antifungal drugs are key to successful treatment. © Association of Surgeons of India 2022.

Entities:  

Keywords:  Aspergillosis; Mucormycosis; Urinary bladder

Year:  2022        PMID: 36065434      PMCID: PMC9430012          DOI: 10.1007/s12262-022-03556-4

Source DB:  PubMed          Journal:  Indian J Surg        ISSN: 0973-9793            Impact factor:   0.437


Introduction

Mucormycosis in the urinary bladder is extremely rare with only one case reported in the literature [1]. Mucormycosis of the urinary bladder is usually associated with renal mucormycosis. Risk factors for mucormycosis are diabetes mellitus, chronic kidney disease, malignancies, immunosuppressive therapy and recently COVID-19 infection [2]. It is caused by fungi of the order Mucorales which includes several species. It causes infection in immunocompromised patients [3]. We present a case of a 55-year-old diabetic patient with fever, difficulty in urination and deranged creatinine and ultimately diagnosed with urinary bladder mucormycosis.

Case Summary

A 55-year-old gentleman presented with low-grade fever, dysuria, flank pain and obstructive urinary symptoms. He was a known diabetic on oral hypoglycaemic drugs. He has no history of dyspnoea, chest pain, facial pain, recent COVID-19 infection or intake of any immunosuppressive therapy. On clinical examination, abdomen was normal, and the renal angle was nontender. Blood investigation results were as follows: haemoglobin 12.5 g/dl, TLC 11,500/mm3, urea 35 mg/dl, creatinine 2.5 mg/dl, and electrolytes were normal. Ultrasound and noncontract CT scan abdomen were suggestive of right mild hydronephrosis with a thickened urinary bladder filled with internal echoes (Fig. 1a, b). Cystoscopy was planned because of hydronephrosis and echogenic contents in the urinary bladder which revealed creamy yellow necrotic material in the urinary bladder (Fig. 2). Evacuation of necrotic material was done and sent for histopathology. Ureteric orifices were normal, and no mass was seen in the urinary bladder. The histopathologic examination of the necrotic material was suggestive of mucormycosis and occasional aspergillosis hyphae (Fig. 3). He was started on posaconazole and improved.
Fig. 1

(a) Noncontrast CT scan showing right mild hydronephrosis (red arrow), (b) urinary bladder mildly distended (orange arrow)

Fig. 2

(a) Cystoscopy showed yellowish-white material (red arrow) in urinary bladder, (b) cystoscopy showed normal ureteric orifice (yellow arrow) and necrotic mass

Fig. 3

(a) Photograph showing broad hyphae of Mucor, thin hyphae of Aspergillus and broad hyphae of Mucor (H & E 100 ×), (b) hyphae of Mucor revealing obtuse angle branching (GMS 400 ×), (c) broad hyphae of Mucor (blue), thin hyphae of Aspergillus (black) (PAS stain 400 ×)

(a) Noncontrast CT scan showing right mild hydronephrosis (red arrow), (b) urinary bladder mildly distended (orange arrow) (a) Cystoscopy showed yellowish-white material (red arrow) in urinary bladder, (b) cystoscopy showed normal ureteric orifice (yellow arrow) and necrotic mass (a) Photograph showing broad hyphae of Mucor, thin hyphae of Aspergillus and broad hyphae of Mucor (H & E 100 ×), (b) hyphae of Mucor revealing obtuse angle branching (GMS 400 ×), (c) broad hyphae of Mucor (blue), thin hyphae of Aspergillus (black) (PAS stain 400 ×)

Discussion

Mucormycosis is an infection due to fungi (order Mucorales) of species Rhizopus, Mucor, Cunninghamella, Apophysomyces, Lichtheimia and Rhizomucor [4]. These are angioinvasive fungi, which invade kidneys haematogenously as part of a multi-organ disease, although isolated renal involvement is also reported [1, 3] Mucor is a ubiquitous fungus that reaches the human body through spores entrapped in nasal turbinates or through ingestion, inhalation and interrupted skin. This infection is seen commonly in diabetics, immunocompromised patients such as allograft recipients, HIV patients, patients with malignancy and intravenous (IV) drug abusers [1, 5]. The virulence factor involved in the pathogenesis of Mucorales are high-affinity iron permease (FTR1), spore coat protein (Cot H) and ADP-ribosylation factor which allows fungi to tolerate a low iron environment, impairing host defences and growth of Mucorales [6]. Neutrophils are the mainstay to mount a response against Mucor, hence patients with neutropenia or dysfunction in neutrophils (steroid use, diabetes mellitus) result in fulminant fungal infection [7]. On basis of location, mucormycosis can be divided into rhinocerebral, pulmonary, cutaneous, gastrointestinal, disseminated and uncommon presentations [8]. Having an index suspicion and timely diagnosis is required for successful treatment of mucormycosis. In genitourinary organs, mucormycosis is reported in kidneys, although involvement of other organs is reported occasionally. It can present with flank pain, fever, acute kidney injury and lump. Diagnosis is by clinical suspicion, radiology, smear examination, culture, cytopathology and direct examination under a microscope. When culture is not available or cannot be done, histopathology is the mainstay of diagnosis [9]. Examination with stains haematoxylin and eosin (H&E) or Grocott methenamine-silver (GMS) or periodic acid-Schiff (PAS) stains show typical broad, nonseptate, irregular, ribbon-shaped (typically 6- to 25-µm diameter) and irregular branching at 45–90°. Histopathology from tissue shows necrosis and angioinvasion with neutrophils as the predominant inflammatory response. A granulomatous response may be seen in delayed stages [10]. Treatment can be medical as well as surgical as per the condition of the patient. Amphotericin B (liposomal) is the first-line treatment with posaconazole and isavuconazole as alternatives. Espejo et al. reported a case of bladder mass detected and managed medically. They described the presence of a fungal mass in a patient with DM and CKD (chronic kidney disease) [1]. In a case series by Devana et al., 15 patients with isolated renal mucormycosis were described. Ten underwent unilaterally nephrectomy and 2 underwent bilateral nephrectomy, whereas 2 were managed medically for mucormycosis [2]. Our patient complained of low-grade fever and difficulty in urination with deranged creatinine. Investigations suggested right mild hydronephrosis with no renal changes of mucormycosis with echogenic contents in the urinary bladder. The patient was taken up for cystoscopy and stenting. On cystoscopy, elongated, creamy yellow material was seen in the urinary bladder. Histopathology suggested mucormycosis in the urinary bladder. He was started on oral posaconazole and improved considerably. Follow-up investigation revealed normal kidneys and normal creatinine (1.1 mg/dl).

Conclusions

Isolated urinary bladder mucormycosis is extremely rare. Mucormycosis is a rare opportunistic fungal infection with high morbidity and mortality with rare bladder involvement. It can also remain asymptomatic; timely diagnosis and starting antifungal drugs are key for successful treatment.
  10 in total

Review 1.  Epidemiology and clinical manifestations of mucormycosis.

Authors:  George Petrikkos; Anna Skiada; Olivier Lortholary; Emmanuel Roilides; Thomas J Walsh; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2012-02       Impact factor: 9.079

Review 2.  Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives.

Authors:  Kyung J Kwon-Chung
Journal:  Clin Infect Dis       Date:  2012-02       Impact factor: 9.079

Review 3.  Host defenses against zygomycetes.

Authors:  Emmanuel Roilides; Dimitrios P Kontoyiannis; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2012-02       Impact factor: 9.079

Review 4.  Breaking the Mold: A Review of Mucormycosis and Current Pharmacological Treatment Options.

Authors:  Treavor T Riley; Christina A Muzny; Edwin Swiatlo; Davey P Legendre
Journal:  Ann Pharmacother       Date:  2016-06-15       Impact factor: 3.154

5.  Isolated Renal Mucormycosis in Immunocompetent Hosts: Clinical Spectrum and Management Approach.

Authors:  Sudheer K Devana; Vijayanth G Gupta; Ravimohan S Mavuduru; Girdhar S Bora; Aditya P Sharma; Kalpesh M Parmar; Santosh Kumar; Uttam K Mete; Shrawan K Singh; Arup K Mandal; Nandita Kakkar; Nirmalya Banerjee; Anup Ghosh
Journal:  Am J Trop Med Hyg       Date:  2019-04       Impact factor: 2.345

6.  Ten years' experience in zygomycosis at a tertiary care centre in India.

Authors:  A Chakrabarti; A Das; A Sharma; N Panda; S Das; K L Gupta; V Sakhuja
Journal:  J Infect       Date:  2001-05       Impact factor: 6.072

7.  [Bladder mucormycosis. Report of one case].

Authors:  María Paz Pérez de la Espejo; Rafael Barrero Candau; David Chinchón Espino; Pedro Campoy Martínez
Journal:  Arch Esp Urol       Date:  2004 Jan-Feb       Impact factor: 0.436

Review 8.  Mucormycosis.

Authors:  Julie M Steinbrink; Marisa H Miceli
Journal:  Infect Dis Clin North Am       Date:  2021-06       Impact factor: 5.982

9.  Mucormycosis (zygomycosis) of renal allograft.

Authors:  Krishan L Gupta; Kusum Joshi; Harbir S Kohli; Vivekanand Jha; Vinay Sakhuja
Journal:  Clin Kidney J       Date:  2012-11-08

10.  Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium.

Authors:  J Peter Donnelly; Sharon C Chen; Carol A Kauffman; William J Steinbach; John W Baddley; Paul E Verweij; Cornelius J Clancy; John R Wingard; Shawn R Lockhart; Andreas H Groll; Tania C Sorrell; Matteo Bassetti; Hamdi Akan; Barbara D Alexander; David Andes; Elie Azoulay; Ralf Bialek; Robert W Bradsher; Stephane Bretagne; Thierry Calandra; Angela M Caliendo; Elio Castagnola; Mario Cruciani; Manuel Cuenca-Estrella; Catherine F Decker; Sujal R Desai; Brian Fisher; Thomas Harrison; Claus Peter Heussel; Henrik E Jensen; Christopher C Kibbler; Dimitrios P Kontoyiannis; Bart-Jan Kullberg; Katrien Lagrou; Frédéric Lamoth; Thomas Lehrnbecher; Jurgen Loeffler; Olivier Lortholary; Johan Maertens; Oscar Marchetti; Kieren A Marr; Henry Masur; Jacques F Meis; C Orla Morrisey; Marcio Nucci; Luis Ostrosky-Zeichner; Livio Pagano; Thomas F Patterson; John R Perfect; Zdenek Racil; Emmanuel Roilides; Marcus Ruhnke; Cornelia Schaefer Prokop; Shmuel Shoham; Monica A Slavin; David A Stevens; George R Thompson; Jose A Vazquez; Claudio Viscoli; Thomas J Walsh; Adilia Warris; L Joseph Wheat; P Lewis White; Theoklis E Zaoutis; Peter G Pappas
Journal:  Clin Infect Dis       Date:  2020-09-12       Impact factor: 9.079

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.